Explore All Access
Check if your research matches the topics covered in Biologics: Targets and Therapy?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Biologics: Targets and Therapy : Impact Factor & More
eISSN: 1177-5491pISSN: 1177-5475
Open AccessShare this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Biologics: Targets and Therapy Key Metrics
CiteScore 
5.7
SJR
Q2Oncology
SNIP
1.05
Time to Accept
3
Mo
Time to Publish
View Chart Mo
Time to Publish
Sign up now and unlock a detailed chart of Time to publish for this journal
% of papers by time taken from submission to publication
0 to 3 months17%
4 to 6 months72%
7 to 9 months11%
Above 9 months0%
Did you find this useful?
Biologics: Targets and Therapy Journal Specifications
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2007 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Biologics: Targets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Biologics: Targets and Therapy
Cholinesterase Inhibitor Reveals Synergistic Potential for Neural Stem Cell-Based Therapy in the 5xFAD Mouse Model of Alzheimer's Disease.
- 1 Dec 2024
- Biologics : targets & therapy
Comparison of Innovative and Conventional Methods in Biosimilar Bridging Studies with Multiple References
- 1 Dec 2024
- Biologics: Targets and Therapy
Expression Levels of lncRNA NEAT1, miRNA-21, and IL-17 in a Group of Egyptian Patients with Behçet's Disease: Relation to Disease Manifestations and Activity.
- 1 Nov 2024
- Biologics : targets & therapy
Short and Medium Chain Fatty Acids in a Cohort of Naïve Multiple Sclerosis Patients: Pre- and Post-Interferon Beta Treatment Assessment.
- 1 Nov 2024
- Biologics : targets & therapy
Effectiveness and Persistence of Anti-TNFα Treatment in Patients with Rheumatoid Arthritis - A 7 Years Real-World Cohort Study.
- 1 Nov 2024
- Biologics : targets & therapy
Feasibility and Tolerability of Anlotinib Plus PD-1 Inhibitors for Previously-Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.
- 1 Nov 2024
- Biologics : targets & therapy
Cholinesterase Inhibitor Reveals Synergistic Potential for Neural Stem Cell-Based Therapy in the 5xFAD Mouse Model of Alzheimer's Disease.
- 1 Dec 2024
- Biologics : targets & therapy
Comparison of Innovative and Conventional Methods in Biosimilar Bridging Studies with Multiple References
- 1 Dec 2024
- Biologics: Targets and Therapy
Expression Levels of lncRNA NEAT1, miRNA-21, and IL-17 in a Group of Egyptian Patients with Behçet's Disease: Relation to Disease Manifestations and Activity.
- 1 Nov 2024
- Biologics : targets & therapy
Short and Medium Chain Fatty Acids in a Cohort of Naïve Multiple Sclerosis Patients: Pre- and Post-Interferon Beta Treatment Assessment.
- 1 Nov 2024
- Biologics : targets & therapy
Effectiveness and Persistence of Anti-TNFα Treatment in Patients with Rheumatoid Arthritis - A 7 Years Real-World Cohort Study.
- 1 Nov 2024
- Biologics : targets & therapy
Feasibility and Tolerability of Anlotinib Plus PD-1 Inhibitors for Previously-Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.
- 1 Nov 2024
- Biologics : targets & therapy
Compare Similar Journals with Biologics: Targets and Therapy
Select Journals to Compare with Biologics: Targets and Therapy
Total journals - 9
You can select up to 3 Journals at a time
Dermatologic Therapy
Publisher: WILEY-HINDAWI
eNeurologicalSci
Publisher: Elsevier
Journal of the Neurological Sciences
Publisher: ELSEVIER
Revue Neurologique
Publisher: MASSON EDITEUR
Multiple Sclerosis and Related Disorders
Publisher: ELSEVIER SCI LTD
Neurological Sciences
Publisher: SPRINGER-VERLAG ITALIA SRL
Clinical Neuropharmacology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
BMC Neurology
Publisher: BMC
Journal of Neuroimmunology
Publisher: ELSEVIER
0 Journals Selected to compare with
Biologics: Targets and Therapy
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on Biologics: Targets and Therapy
How long has Biologics: Targets and Therapy been actively publishing? 
Biologics: Targets and Therapy has been in operation since 2007 till date.
What is the publishing frequency of Biologics: Targets and Therapy?
Biologics: Targets and Therapy published with a Continuous publication frequency.
How many articles did Biologics: Targets and Therapy publish last year?
In 2023, Biologics: Targets and Therapy publsihed 17 articles.
What is the eISSN & pISSN for Biologics: Targets and Therapy?
For Biologics: Targets and Therapy, eISSN is 1177-5491 and pISSN is 1177-5475.
What is Citescore for Biologics: Targets and Therapy?
Citescore for Biologics: Targets and Therapy is 5.7.
What is SNIP score for Biologics: Targets and Therapy?
SNIP score for Biologics: Targets and Therapy is 1.05.
What is the SJR for Biologics: Targets and Therapy?
SJR for Biologics: Targets and Therapy is Q2.
Who is the publisher of Biologics: Targets and Therapy?
DOVE MEDICAL PRESS LTD is the publisher of Biologics: Targets and Therapy.
